Nestlé Health Science Acquisitions

Nestle Health Science

Nestlé Health Science aims to pioneer a new industry between the traditional nutrition and pharmaceutical industries through the development of science-based personalised nutritional solutions and shaping a new approach to disease prevention and management.

In this context, Nestlé Health Science has made several acquisitions and investments:


Pamlab: Acquired in 2012, specialises in medical food products for use under medical supervision in the nutritional management of patients with mild cognitive impairment, depression and diabetic peripheral neuropathy. Read more:

Prometheus Laboratories: Acquired in 2011, specialises in diagnostics and licensed speciality pharmaceuticals in gastroenterology (GI) and oncology. Read more:

CM&D Pharma: Acquired in 2011, specialises in the development of products for patients with chronic conditions like chronic kidney disease and gastrointestinal. Read more:

Vitaflo: Acquired in 2010, develops and markets clinical nutritional solutions for infants, children and adults with genetic disorders that affect how food is processed by the body. Read more:

Partnerships & Joint ventures

Nutrition Science Partners Limited (NSP): A 50/50 joint venture formed between Nestlé Health Science and the pharmaceutical and healthcare group Chi-Med in 2012. NSP focuses on gastrointestinal health and may in the future expand into the metabolic disease and brain health areas. Read more:

Accera: In which Nestlé Health Science acquired a minority stake in 2012, specialises in neurodegenerative disorders, like Alzheimer’s Disease. Read more:

Vital Foods: In which Nestlé Health Science acquired a minority stake in 2011, is active in the development of kiwifruit-based solutions for gastrointestinal conditions. Read more: